An impressive data set on progressive free survival (PFS) demonstrated by Roche's IMpower150 study in non-squamous non-small cell lung cancer (NSCLC) was nonetheless overshadowed at the American Association for Cancer Research (AACR) meeting April 16 by rival trial presentations - and observers say the jury will remain out about IMpower150's four-drug regime until overall survival data is presented later this year.
An updated analysis from Roche’s IMpower150 showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapies carboplatin and paclitaxel significantly improved progression-free survival (PFS) by 39% across all PD-L1 subgroups (ITT-WT, hazard ratio [HR]=0.61; p<0.0001%; CI: 0.51-0.72), including in people whose tumors are considered PD-L1-negative, compared to Avastin plus chemotherapy alone